2026-08-31Application Proof
ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.普莱医药（江苏）股份有限公司
On December 18, 2025, the BIOSECURE Act (the “BIOSECURE Act”) was enacted as Section 851 of the National Defense Authorization Act for Fiscal Year 2026 (the “FY2026 National Defense Authorization Act”).
Summary · p. 14
The company's explanation, the adviser's view and the page in the filing: see MattersWe have identified potential alternative service providers for relevant preclinical research, clinical research and CDMO services, including established CROs and CDMOs with experience supporting international regulatory submissions, which are generally capable of providing comparable services on commercially reasonable terms and supporting submissions to the FDA and the NMPA.
Summary · p. 14